{"id":14962,"date":"2020-01-13T09:19:03","date_gmt":"2020-01-13T14:19:03","guid":{"rendered":"https:\/\/medicarereport.org\/?p=14962"},"modified":"2020-01-13T09:19:03","modified_gmt":"2020-01-13T14:19:03","slug":"high-cost-of-multiple-sclerosis-medicines-is-forcing-many-patients-to-take-drastic-actions","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=14962","title":{"rendered":"High cost of multiple sclerosis medicines is forcing many patients to take \u2018drastic actions\u2019"},"content":{"rendered":"<p>(By Ed Silverman for ST<em>A<\/em>T)<\/p>\n<p><span class=\"big-cap-wrap\"><span class=\"big-cap\">T<\/span><\/span>he high cost of multiple sclerosis treatments has forced 40% of patients to take \u201cdrastic actions\u201d and alter their use of the medicines, such as cutting back or skipping dosages altogether. And many report the financial burden is not only hurting their lifestyle, but impairing their ability to save for retirement or college for their children, a new survey found.\u00a0 Continue reading article <a href=\"https:\/\/www.statnews.com\/pharmalot\/2020\/01\/13\/multiple-sclerosis-drug-prices-2\/\">here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Ed Silverman for STAT) The high cost of multiple sclerosis treatments has forced 40% of patients to take \u201cdrastic<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21,15],"tags":[],"class_list":["post-14962","post","type-post","status-publish","format-standard","hentry","category-health-care-finance","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14962","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14962"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14962\/revisions"}],"predecessor-version":[{"id":14963,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14962\/revisions\/14963"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14962"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14962"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}